Oxford Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Oxford Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,615	Closed	-$382K	–	1792
2019 Q3	$382K	Buy	+2,615	New	+$455K	0.01%	1363
2019 Q1	–	Sell	-1,934	Closed	-$339K	–	1709
2018 Q4	$339K	Buy	+1,934	New	+$386K	0.01%	1352

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Oxford Asset Management's CRBP Position: Q4 2019 in Review

Oxford Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 2,615 shares — an estimated $382K sold.

Oxford Asset Management first reported a position in CRBP in Q4 2018 and held it in 2 quarters. The position peaked at $382K in Q3 2019. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

Oxford Asset Management reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 2,615 Corbus Pharmaceuticals shares in Q4 2019, an estimated $382K.
Oxford Asset Management first reported a position in Corbus Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Oxford Asset Management's Corbus Pharmaceuticals position peaked at $382K in Q3 2019.
105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.